957results about How to "Improved prognosis" patented technology

The invention provides an artificial antigen presenting cell (AAPC) comprising a eukaryotic cell expressing an antigen presenting complex comprising a human leukocyte antigen (HLA) molecule of a single type, at least one exogenous accessory molecule and at least one exogenous T cell-specific epitope. Methods of use for activation of T lymphocytes are also provided.

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and / or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

The present invention relates to methods for the diagnosis and evaluation of stroke and stroke sub-type. A variety of bio-markers are disclosed for assembling a panel for such diagnosis and evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects: the invention provides methods for early detection and differentiation of stroke subtypes, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for hemorrhagic transformation after thrombolyic therapy. Methods are disclosed that provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

It is intended to provide a drug for improving prognosis for subarachnoid hemorrhage which contains, as the active ingredient, at least one member selected from the group consisting of eicosapentaenoic acid (EPA) and pharmaceutically acceptable salts and esters thereof, and a method of improving prognosis for subarachnoid hemorrhage which comprises orally or gastrically administering the above drug.

The present invention provides a technology called Pulse-Multiline Excitation or PME. This technology provides a novel approach to fluorescence detection with application for high-throughput identification of informative SNPs, which could lead to more accurate diagnosis of inherited disease, better prognosis of risk susceptibilities, or identification of sporadic mutations. The PME technology has two main advantages that significantly increase fluorescence sensitivity: (1) optimal excitation of all fluorophores in the genomic assay and (2) “color-blind” detection, which collects considerably more light than standard wavelength resolved detection. Successful implementation of the PME technology will have broad application for routine usage in clinical diagnostics, forensics, and general sequencing methodologies and will have the capability, flexibility, and portability of targeted sequence variation assays for a large majority of the population.

The present invention relates to a cage which is inserted between vertebral bodies of a cervical vertebra or spine during an operation for treating a cervical disc disease, myelosis, or fracture of the cervical vertebra or spine, and more particularly, to a cage with spikes, including upper and lower spikes which are attached to a clip inserted into a main body of the cage, unfolded upward and downward from the main body, and locked to vertebral bodies of a cervical vertebra or spine positioned at the top and bottom of the cage such that the cage is fixed and locked between the vertebral bodies.

The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and / or progression to surgery.

The present invention provides a novel system of hardware designed to capture and process in real time clinical observations of patient responses and reactions in different clinical and patient settings and situations, comprising: a patient biometric data recording system in a clinical office, a mobile real time episode or event data recording device syste or a wearable device recording system.

Methods and compositions for evaluating the prognosis of a breast cancer patient, particularly an early-stage breast cancer patient, are provided. The methods of the invention comprise detecting expression of at least one, more particularly at least two, biomarker(s) in a body sample, wherein overexpression of the biomarker or a combination of biomarkers is indicative of breast cancer prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The biomarkers of the invention are proteins and / or genes whose overexpression is indicative of either a good or bad cancer prognosis. Biomarkers of interest include proteins and genes involved in cell cycle regulation, DNA replication, transcription, signal transduction, cell proliferation, invasion, proteolysis, or metastasis. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques.

Methods are disclosed for the capture, detection, separation, isolation and quantification of contaminants in a starting material. Also disclosed are competitive assay methods for the detection and quantification of contaminants in a starting material. Kits for use with the method are disclosed as well. A system for capturing, separating and / or concentrating contaminants from a material is also presented. The system captures, separates and / or concentrates contaminants such as bacteria, viruses, other microorganisms, and / or larger items, such as insects, from a variety of materials, such as food, and environmental and clinical materials. In general, the system uses a rotating magnetic field to mix the material with magnetic particles to capture the target contaminants, and a fixed magnetic field to separate and concentrate the captured target contaminants.

The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of populations that are positive and negative for estrogen receptor expression. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and / or diagnosis of cells and tissue in breast cancer as well as for the study and / or determination of prognosis of a patient, including breast cancer survival.

A system and method is provided for fault detection in a turbine engine. The fault detection system and method uses discrete event system modeling to provide improved fault diagnosis and prognosis. The fault detection system and method receives sensor taken at multiple dynamic events occurring in different time windows. An event determination mechanism evaluates the received sensor data to determine if specified events have occurred. Indications of the occurrence of specified events are then passed to a discrete event system model. The discrete event system model analyzes the timing and sequencing of the event occurrences to determine if a fault has occurred. This method does not require a detailed modeling of the system, and thus can be applied to complex systems such as turbine engines.

A method is provided, including identifying an electrical stimulation protocol as being suitable for augmenting genesis of one or more cell populations in at least one brain region of the subject. The cell genesis is augmented by applying the identified stimulation protocol to an SPG, a greater palatine nerve, a branch of the greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, a lesser deep petrosal nerve, a maxillary nerve, a branch of the maxillary nerve, a nasopalatine nerve, a peripheral site that provides direct or indirect afferent innervation to the SPG, or a peripheral site that is directly or indirectly efferently innervated by the SPG.

Methods are provided for detecting, separating, isolating and quantifying contaminants in starting materials by separating the contaminant from the starting material using a bead coupled to an affinity moiety and quantum dot-labeling the contaminant. The contaminant is detected by the characteristic emission spectrum of the quantum dot. Also, competitive binding methods are provided wherein the starting material and a control material are contacted with a quantum dot coupled to an affinity moiety capable of binding the contaminant and a competitor complex. A decrease in the intensity of the characteristic emission spectrum of the quantum dot associated with the competitor complex from the starting material as compared to that of the control material is indicative of the presence of the contaminant in the starting material.

Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication / cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided.

Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma.

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.

A diagnostic drug and a diagnostic kit for autoimmune diseases including at least one of a polypeptide selected from an HMG-1 family, a polypeptide selected from an HMG-2 family, a fragment thereof which is reactable with an antibody of an autoimmune disease patient, and a method for detecting an antibody of an autoimmune disease patient using the same are provided.

A urinary directional device for improving the directional urination and health of a male user is provided, in which the device comprises a conduit for the passage of urine and having a proximal end adapted for engagement with the penis of the user and a distal end having a distal aperture to enable the passage of urine from the conduit, the device having an interior surface providing one or more of a cleansing, an anti-bacterial or antiseptic or an anti-fungal function whereby the penis of the user can be cleansed by wiping on the interior surface of the device after urination and the device optionally further comprising a health detection indicator capable of indicating abnormalities in urine indicative of disease or health-related conditions.

The present invention relates to methods of detection, prognosis and treatment of breast cancer using a plurality genes or gene products present in normal and neoplastic cells, tissues and bodily fluids. Gene products relate to compositions comprising the nucleic acids, polypeptides, antibodies, post translational modifications (PTMs), variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. Additional uses include identifying, monitoring, staging, imaging and treating cancer and non-cancerous disease states in breast as well as determining the effectiveness of therapies alone or in combination for an individual. Therapies include gene therapy, therapeutic molecules including but not limited to antibodies, small molecules and antisense molecules.

A method of using an integrated intraluminal imaging system includes an optical coherence tomography interferometer (OCT), an ultrasound subsystem (US) and a phase resolved acoustic radiation force optical coherence elastography subsystem (PR-RAF-OCE). The steps include performing OCT to generate a returned optical signal, performing US imaging to generate a returned ultrasound signal, performing PR-ARF-OCE to generate a returned PR-ARF-OCE signal by generating a amplitude modulated ultrasound beam or chirped amplitude modulated ultrasound beam to frequency sweep the acoustic radiation force, measuring the ARF induced tissue displacement using phase resolved OCT method, and the frequency dependence of the PR-ARF-OCE signal, processing the returned optical signal, the returned ultrasound signal and the measured frequency dependence of the returned PR-ARF-OCE optical coherence elastographic signal to quantitatively measure the mechanical properties of the identified tissues with both spectral and spatial resolution using enhanced materials response at mechanically resonant frequencies to distinguish tissues with varying stiffness, to identify tissues with different biomechanical properties and to measure structural and mechanical properties simultaneously.

The invention related to methods of diagnosis and prognosis of cancer, the methods comprising determining the level of one or more gene products. In addition, the invention relates to modulators of the gene products for use in treatment of cancer. The genes include EIA-induced genes and Numb.